Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

Sponsor

Tianjin Medical University Cancer Institute and Hospital (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT04846634

Collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Industry)

Enrollment

Location

Arms

Anticipated Duration (Months)

1.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a multicenter, randomized, open label, phase II study.

Condition or Disease	Intervention/Treatment	Phase
Resectable Locally Advanced Non-small Cell Lung Cancer	Drug: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel Drug: Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel Drug: Penpulimab+Anlotinib	Phase 2

Detailed Description

This is a multicenter, randomized, open label, phase II study assessing the efficacy and safety of penpulimab plus chemotherapy or penpulimab plus anlotinib or penpulimab plus chemotherapy and anlotinib as neoadjuvant/adjuvant treatment in patients with resectable locally advanced non-small cell lung cancer. Eligible patients will be randomized to receive either penpulimab (200mg, iv, Q3W) plus chemotherapy (platinum based chemotherapy) or penpulimab (200mg, iv, Q3W) plus anlotinib (12mg, po, day 1-14, Q3W) or penpulimab (200mg, iv, Q3W) plus chemotherapy (platinum based chemotherapy) and anlotinib (12mg, po, day 1-14, Q3W) in a 1:1:1 ratio.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

90 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)

Anticipated Study Start Date :

Aug 1, 2021

Anticipated Primary Completion Date :

Mar 1, 2023

Anticipated Study Completion Date :

Feb 1, 2028

Arms and Interventions

Arm	Intervention/Treatment
Experimental: neoadjuvant Penpulimab + chemotherapy followed by adjuvant Penpulimab	Drug: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel A cycle of treatment is defined as 21 days of once daily treatment. Other Names: Investigational Product
Experimental: neoadjuvant Penpulimab + chemotherapy + Anlotinib followed by adjuvant Penpulimab + Anlotinib.	Drug: Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel A cycle of treatment is defined as 21 days of once daily treatment. Other Names: Investigational Product
Experimental: neoadjuvant Penpulimab + Anlotinib followed by adjuvant Penpulimab + Anlotinib.	Drug: Penpulimab+Anlotinib A cycle of treatment is defined as 21 days of once daily treatment. Other Names: Investigational Product

Arm

Intervention/Treatment

Experimental: neoadjuvant Penpulimab + chemotherapy followed by adjuvant Penpulimab

Drug: Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel

A cycle of treatment is defined as 21 days of once daily treatment.

Other Names:

Investigational Product

Experimental: neoadjuvant Penpulimab + chemotherapy + Anlotinib followed by adjuvant Penpulimab + Anlotinib.

Drug: Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel

A cycle of treatment is defined as 21 days of once daily treatment.

Other Names:

Investigational Product

Experimental: neoadjuvant Penpulimab + Anlotinib followed by adjuvant Penpulimab + Anlotinib.

Drug: Penpulimab+Anlotinib

A cycle of treatment is defined as 21 days of once daily treatment.

Other Names:

Investigational Product

Outcome Measures

Primary Outcome Measures

Major pathological response (MPR) [About 3-6 weeks following completion of surgery.]

Secondary Outcome Measures

Objective response rate (ORR) [Within 7 days before surgery.]
1 year Event-Free Survival rate [Up to 5 Years from randomization]
Event-Free Survival (EFS) [Up to 5 years from randomization.]
Overall survival (OS) [Up to 5 years from randomization.]
Incidence of adverse events (AEs)/serious adverse events (SAEs) [Up to 5 Years from randomization]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Early stage IIB-IIIB (N2), operable non-small cell lung cancer, confirmed in tissue.
Epidermal growth factor receptor/anaplastic lymphoma kinase/ROS1 gene fusions mutation was negative in primary tumor or lymph node metastasis.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
Lung function capacity capable of tolerating the proposed lung surgery.
Patients had never received surgery, chemotherapy, radiotherapy or biotherapy.

Exclusion Criteria:

Large cell carcinoma and mixed cell lung cancer.
Any systemic anti-cancer treatment for NSCLC, including cytotoxic drug therapy, immunotherapy, experimental treatment.
Prior treatment with local radiotherapy.
Prior treatment with any drug that targets T cell co-stimulations pathways (such as checkpoint inhibitors).
Prior treatment with antilotinib and other antiangiogenic drugs.
History of hypersensitivity to any active or inactive ingredient of Penpulimab, Anlotinib or chemotherapy.
Patients with multiple factors affecting oral medication (e.g. inability to swallow, chronic diarrhea, and intestinal obstruction, etc.).
Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis that required steroid treatment, or any evidence of clinically active interstitial lung disease.
Patients whose tumor has invaded important blood vessels or whose tumor is likely to invade important blood vessels and cause fatal massive hemorrhage during follow-up study.
Patients who have had arteriovenous thrombosis events within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism.
Pregnant or lactating women.
History of neurological or mental disorders, including epilepsy or dementia.